Kirin Pharma To Close Three Of Four R&D Sites In Japan
This article was originally published in PharmAsia News
Kirin Pharma of Japan says it will close all but one of its R&D sites within the next three years. The firm, a subsidiary of Kirin Holdings, has four such sites in the Gunma Prefecture employing about 200 researchers. The company said the workers would be reassigned as it sells the closing facilities. Kirin R&D work is to be done in conjunction with another subsidiary, Kyowa Hakko Kogyo, after a merger scheduled for October. (Click here for more - a subscription may be required
You may also be interested in...
By outlicensing early-stage compounds, Japanese pharma can gain benefits beyond receiving licensing fees, including de-risking Japanese development, according to a U.S. biotech CEO
Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.
Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.